Royalty Pharma PLC (RPRX) To Go Ex-Dividend on February 20th

Royalty Pharma PLC (NASDAQ:RPRX) announced a quarterly dividend on Friday, January 9th. Investors of record on Friday, February 20th will be given a dividend of 0.235 per share by the biopharmaceutical company on Tuesday, March 10th. This represents a c) annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, February 20th. This is a 6.8% increase from Royalty Pharma’s previous quarterly dividend of $0.22.

Royalty Pharma has a dividend payout ratio of 17.5% indicating that its dividend is sufficiently covered by earnings. Analysts expect Royalty Pharma to earn $4.86 per share next year, which means the company should continue to be able to cover its $0.88 annual dividend with an expected future payout ratio of 18.1%.

Royalty Pharma Trading Down 0.2%

Shares of NASDAQ:RPRX opened at $40.17 on Friday. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $23.19 billion, a PE ratio of 30.43, a P/E/G ratio of 1.93 and a beta of 0.43. Royalty Pharma has a 1 year low of $27.47 and a 1 year high of $41.70. The firm has a fifty day moving average price of $39.19 and a 200 day moving average price of $37.28.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.06. The company had revenue of $609.29 million for the quarter, compared to analyst estimates of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. Analysts expect that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Insider Activity

In other news, EVP Marshall Urist sold 20,000 shares of the firm’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $39.32, for a total value of $786,400.00. Following the sale, the executive vice president owned 100,000 shares in the company, valued at approximately $3,932,000. This trade represents a 16.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP George W. Lloyd sold 30,654 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $38.50, for a total transaction of $1,180,179.00. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 846,511 shares of company stock valued at $33,011,004. 18.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Royalty Pharma

Several hedge funds have recently made changes to their positions in the stock. Capital International Investors grew its position in Royalty Pharma by 24.4% in the third quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock valued at $960,064,000 after acquiring an additional 5,332,074 shares during the period. Swedbank AB boosted its stake in shares of Royalty Pharma by 0.4% in the 3rd quarter. Swedbank AB now owns 12,200,270 shares of the biopharmaceutical company’s stock valued at $430,426,000 after purchasing an additional 42,800 shares in the last quarter. State Street Corp boosted its stake in shares of Royalty Pharma by 0.8% in the 3rd quarter. State Street Corp now owns 10,272,753 shares of the biopharmaceutical company’s stock valued at $362,423,000 after purchasing an additional 77,815 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Royalty Pharma by 2.2% in the 2nd quarter. Geode Capital Management LLC now owns 8,176,504 shares of the biopharmaceutical company’s stock worth $299,494,000 after purchasing an additional 177,036 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Royalty Pharma during the 2nd quarter worth about $181,388,000. Institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.